Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
10,154
archived clinical trials in
Other Indications

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
Childrens National Medical Center
mi
from
Washington,
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
Riley Hospital for Children
mi
from
Indianapolis, IN
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated:  12/31/1969
Hospital for Sick Children
mi
from
Toronto,
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Status: Enrolling
Updated: 12/31/1969
Hospital for Sick Children
mi
from
Toronto,
Click here to add this to my saved trials
Resin Infiltration to Arrest Early Tooth Decay
Radiographic Progression of Early Caries Lesions After Resin Infiltration
Status: Enrolling
Updated:  12/31/1969
Saunders USADC
mi
from
West Point, NY
Resin Infiltration to Arrest Early Tooth Decay
Radiographic Progression of Early Caries Lesions After Resin Infiltration
Status: Enrolling
Updated: 12/31/1969
Saunders USADC
mi
from
West Point, NY
Click here to add this to my saved trials
Cone Beam CT for Diagnosis of Select Otorhinolaryngology (ENT) Indications at Lower Dose
Cone Beam CT (CS 9300) for Diagnosis of Select Otorhinolaryngology (ENT) Indications at Lower Dose
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Medical Center
mi
from
Baltimore, MD
Cone Beam CT for Diagnosis of Select Otorhinolaryngology (ENT) Indications at Lower Dose
Cone Beam CT (CS 9300) for Diagnosis of Select Otorhinolaryngology (ENT) Indications at Lower Dose
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cone Beam CT for Diagnosis of Select Otorhinolaryngology (ENT) Indications at Lower Dose
Cone Beam CT (CS 9300) for Diagnosis of Select Otorhinolaryngology (ENT) Indications at Lower Dose
Status: Enrolling
Updated:  12/31/1969
Sint-Augustinus Hospital
mi
from
Antwerp,
Cone Beam CT for Diagnosis of Select Otorhinolaryngology (ENT) Indications at Lower Dose
Cone Beam CT (CS 9300) for Diagnosis of Select Otorhinolaryngology (ENT) Indications at Lower Dose
Status: Enrolling
Updated: 12/31/1969
Sint-Augustinus Hospital
mi
from
Antwerp,
Click here to add this to my saved trials
Evaluate the Effectiveness of an Experimental Urethane Dimethacrylate Resin Based Dental Composite Material
Clinical Evaluation of an Experimental Urethane Dimethacrylate Resin Based Composite
Status: Enrolling
Updated:  12/31/1969
University of Rochester, Eastman Institute for Oral Health
mi
from
Rochester, NY
Evaluate the Effectiveness of an Experimental Urethane Dimethacrylate Resin Based Dental Composite Material
Clinical Evaluation of an Experimental Urethane Dimethacrylate Resin Based Composite
Status: Enrolling
Updated: 12/31/1969
University of Rochester, Eastman Institute for Oral Health
mi
from
Rochester, NY
Click here to add this to my saved trials
Mesenchymal Stem Cell Therapy in Multiple System Atrophy
Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural History
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Mesenchymal Stem Cell Therapy in Multiple System Atrophy
Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural History
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.
An Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Mucopolysaccharidosis Type IIIA Disease
Status: Enrolling
Updated:  12/31/1969
Chu Bicetre, Le Kremlin-Bicêtre
mi
from
Paris,
An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.
An Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Mucopolysaccharidosis Type IIIA Disease
Status: Enrolling
Updated: 12/31/1969
Chu Bicetre, Le Kremlin-Bicêtre
mi
from
Paris,
Click here to add this to my saved trials
An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.
An Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Mucopolysaccharidosis Type IIIA Disease
Status: Enrolling
Updated:  12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.
An Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Mucopolysaccharidosis Type IIIA Disease
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.
An Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Mucopolysaccharidosis Type IIIA Disease
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.
An Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Mucopolysaccharidosis Type IIIA Disease
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Oral Alkali Production and Caries Prevention in Children (Longitudinal)
Oral Alkali Production and Caries Prevention in Children (Longitudinal Component)
Status: Enrolling
Updated:  12/31/1969
Dental Clinical Research Unit, University of Florida
mi
from
Gainesville, FL
Oral Alkali Production and Caries Prevention in Children (Longitudinal)
Oral Alkali Production and Caries Prevention in Children (Longitudinal Component)
Status: Enrolling
Updated: 12/31/1969
Dental Clinical Research Unit, University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
Status: Enrolling
Updated:  12/31/1969
Colorado State University
mi
from
Fort Collins, CO
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
Status: Enrolling
Updated: 12/31/1969
Colorado State University
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
Status: Enrolling
Updated:  12/31/1969
Institut de Recherche en Sciences de la Santé
mi
from
Bobo Dioulasso,
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
Status: Enrolling
Updated: 12/31/1969
Institut de Recherche en Sciences de la Santé
mi
from
Bobo Dioulasso,
Click here to add this to my saved trials
Genetic, Dietary and Environmental Influences on Vitamin D Metabolism
Genetic, Dietary and Environmental Influences on Vitamin D Metabolism
Status: Enrolling
Updated:  12/31/1969
Penn State Clinical Research Center
mi
from
University Park, PA
Genetic, Dietary and Environmental Influences on Vitamin D Metabolism
Genetic, Dietary and Environmental Influences on Vitamin D Metabolism
Status: Enrolling
Updated: 12/31/1969
Penn State Clinical Research Center
mi
from
University Park, PA
Click here to add this to my saved trials
Comparison of In-Person Versus Remote Cochlear Implant Candidacy Evaluations
Comparison of Patient & Provider Outcomes With In-Person Versus Remote Cochlear Implant Candidacy Evaluations
Status: Enrolling
Updated:  12/31/1969
University of Kentucky
mi
from
Lexington, KY
Comparison of In-Person Versus Remote Cochlear Implant Candidacy Evaluations
Comparison of Patient & Provider Outcomes With In-Person Versus Remote Cochlear Implant Candidacy Evaluations
Status: Enrolling
Updated: 12/31/1969
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Combination of Lenalidomide and Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL)
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Combination of Lenalidomide and Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL)
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Genetic Susceptibility to Oncogenic Viruses
Genetic Susceptibility to Oncogenic Viruses
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Genetic Susceptibility to Oncogenic Viruses
Genetic Susceptibility to Oncogenic Viruses
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Pilot Study to Evaluate Patient Tolerance and Nursing Ease-of-Use of a Novel Hearing Protection Device
A Pilot Study to Evaluate Patient Tolerance and Nursing Ease-of-Use of a Novel Hearing Protection Device to Reduce Exposure to Excessive Noise Among Patients Undergoing Neonatal Intensive Care
Status: Enrolling
Updated:  12/31/1969
Magee Womens, UPMC Hamot
mi
from
Erie, PA
A Pilot Study to Evaluate Patient Tolerance and Nursing Ease-of-Use of a Novel Hearing Protection Device
A Pilot Study to Evaluate Patient Tolerance and Nursing Ease-of-Use of a Novel Hearing Protection Device to Reduce Exposure to Excessive Noise Among Patients Undergoing Neonatal Intensive Care
Status: Enrolling
Updated: 12/31/1969
Magee Womens, UPMC Hamot
mi
from
Erie, PA
Click here to add this to my saved trials
Investigation of Hypermobility, Biomarkers, and Pain Generators in Chronic Pain Patients
Investigation of Hypermobility, Biomarkers, and Pain Generators in Chronic Pain Patients
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Investigation of Hypermobility, Biomarkers, and Pain Generators in Chronic Pain Patients
Investigation of Hypermobility, Biomarkers, and Pain Generators in Chronic Pain Patients
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Assessing and Addressing Behaviors in Children With Hearing Loss
Assessing and Addressing Behaviors in Children With Hearing Loss
Status: Enrolling
Updated:  12/31/1969
Lexington Hearing and Speech Academy
mi
from
Lexington, KY
Assessing and Addressing Behaviors in Children With Hearing Loss
Assessing and Addressing Behaviors in Children With Hearing Loss
Status: Enrolling
Updated: 12/31/1969
Lexington Hearing and Speech Academy
mi
from
Lexington, KY
Click here to add this to my saved trials
Assessing and Addressing Behaviors in Children With Hearing Loss
Assessing and Addressing Behaviors in Children With Hearing Loss
Status: Enrolling
Updated:  12/31/1969
University of Kentucky
mi
from
Lexington, KY
Assessing and Addressing Behaviors in Children With Hearing Loss
Assessing and Addressing Behaviors in Children With Hearing Loss
Status: Enrolling
Updated: 12/31/1969
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Assessing and Addressing Behaviors in Children With Hearing Loss
Assessing and Addressing Behaviors in Children With Hearing Loss
Status: Enrolling
Updated:  12/31/1969
Heuser Hearing Institute
mi
from
Louisville, KY
Assessing and Addressing Behaviors in Children With Hearing Loss
Assessing and Addressing Behaviors in Children With Hearing Loss
Status: Enrolling
Updated: 12/31/1969
Heuser Hearing Institute
mi
from
Louisville, KY
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Valley Perinatal
mi
from
Scottsdale, AZ
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Valley Perinatal
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Heinen Obstectrics & Gynecology
mi
from
Eunice, LA
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Heinen Obstectrics & Gynecology
mi
from
Eunice, LA
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Newlife Wellness OBGYN
mi
from
Brooklyn, NY
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Newlife Wellness OBGYN
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Lakeshore Women's Specialists
mi
from
Mooresville, NC
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Lakeshore Women's Specialists
mi
from
Mooresville, NC
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Cincinnati Obgyn
mi
from
Cincinnati, OH
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Cincinnati Obgyn
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
James D. Kasten, M.D., Inc.
mi
from
Norwalk, OH
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
James D. Kasten, M.D., Inc.
mi
from
Norwalk, OH
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Regional Obstetrical Consultants
mi
from
Chattanooga, TN
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Regional Obstetrical Consultants
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Texas Maternal-Fetal Medicine
mi
from
Webster, TX
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Texas Maternal-Fetal Medicine
mi
from
Webster, TX
Click here to add this to my saved trials
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Status: Enrolling
Updated:  12/31/1969
University of Alabama
mi
from
Birmingham, AL
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Status: Enrolling
Updated: 12/31/1969
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials